Release Date: 23-Feb-2023
Immune checkpoint inhibitors have been the major reason of success for immunotherapy. With PD-1 and CTLA-4 immune checkpoint inhibitors showing robust response rates both in the patient segment and the commercial segment, there has been a constant need for the discovery of more targets for immune checkpoints. B7-H3 is a newly identified target whose expression has been reported in several human cancers indicating its potential therapeutic use.
CD276 or B7 Homolog 3 Protein (B7-H3) is being considered as a potential regulatory of the anti-tumor immunity as its expression has been associated with antagonistic pathologic features and poor prognosis in disease. Anyhow, its expression is found to be different on tumor cells when compared to normal, healthy cells which have made it easier for the drugs targeting B7-H3 immune checkpoint to distinguish between the two.
Global CD276 Antibody Clinical Trials and Market Sales Forecast 2028 Report Highlights:
Even though there is limited knowledge about the physiological function of this novel immune checkpoint protein, there has been progress in the clinical trials. Despite the fact that there are just approximately 30 drug candidates in clinical trials against B7-H3, the positive results displayed by them have encouraged more studies to move from pre-clinical studies to their respective clinical trials.
Several hypothesized trials have been conducted for numerous cancer indications including; non-small cell lung cancer, breast cancer, cervical cancer, ovarian cancer, renal cancer, prostate cancer but the research is not just limited to them. Bio-Thera solutions has announced that it has started its first patient dose in phase I study from its drug BAT-8009 which is an antibody drug conjugate for the treatment of patients with advanced solid tumors.
The commercial stage pharmaceutical company has begun the multicenter, open-label phase I clinical study to investigate BAT8009 against B7-H5 immune checkpoint protein. The inhibitory drug is developed using Bio-Thera’s proprietary technology and has a potential to become the first-in-class antibody drug conjugate that targets B7-H3. The clinical trial is designed to test the safety and efficacy of BAT8009 with key objectives of the study to determine the maximum tolerated dose and recommended dose of the expected phase II while also evaluating the pharmacokinetics and preliminary efficacy in patients with solid tumors.
Furthermore, MacroGenics is testing its investigational drug MGC108 in patients with urologic cancers including prostate cancer who have received one prior androgen receptor axis targeted therapy and one prior taxane-containing regimen, in an open label study. This drug is an antibody drug conjugate that targets solid tumors which express B7-H3 immune checkpoint inhibitor. The trial consists of two stages with individuals receiving either selected dose of MGC108 or a comparator every 4 weeks.
In the race to find cure, the clinical trials for solid tumors have been gaining certain momentum and are continuing to pave the way for the discovery and approval of effective new anti-cancer targets. With B7-H3 targeted immune checkpoint inhibitors being actively targeted in solid tumors and showing robust clinical response, it is predictable that soon a drug might be approved which will be targeting B7-H3 immune checkpoint protein.
The surge in incidence of cancer cases, there has been an increasing adoption towards novel therapeutics and the need to fulfill the unmet needs of patients, the market segment has been slowly expanding and embracing the growth of B7-H3 targeted immune checkpoint inhibitors. This report aims to provide information about the current market scenario for this segment of the industry and highlighting the frontrunners that are actively developing drugs against B7-H3 immune checkpoint protein.
It is soon that a drug will enter the market and whichever company it may be, it is certain that they will definitely have an upper edge in this market segment of B7-H3 targeted immune checkpoint inhibitors. Some of the key market players include; AbbVie, YmAb Therapeutics, Fate Therapeutics, GT Biopharma, BioAtla, Daiichi Sankyo, MacroGenics and several others. Our report also briefly discusses about the factors that will be limited market opportunities and factors that will cause market expansion.